drugset / Trial / NCT03471624

Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)

NCT03471624

Phase 4 Completed 270 enrolled Stanford University Gilead Sciences · collab
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment

Timeline

Start
2018-05-01
Primary completion
2022-04-19
Completion
2022-04-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject tenofovir alafenamide Small molecule 25 mg